Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia.
Level 5 - mechanism / opinion, no new human data
Animal study without human participants.
PubMed 23722711 · doi:10.1152/japplphysiol.00221.2013
What was done
Researchers conducted a dose-escalation experiment in 20-kg swine exposed to hyperbaric hyperoxia at depths of 132 or 165 feet of seawater (fsw) to test whether vigabatrin prevents central nervous system oxygen toxicity. Swine received saline or vigabatrin (180 mg/kg or 250 mg/kg). Outcomes included seizure latency, functional electroretinography, and retinal histology to assess acute retinotoxicity.
What was found
Saline controls had seizure latencies of 11 min at 132 fsw and 7 min at 165 fsw. Vigabatrin at 180 mg/kg increased seizure latency to 27 min at 132 fsw and 13 min at 165 fsw. Vigabatrin at 250 mg/kg abolished seizure activity at all depths. Functional electroretinogram and retinal histology showed no signs of retinal toxicity in any vigabatrin-treated animals. In the 250 mg/kg group, central nervous system oxygen toxicity was absent, but pulmonary oxygen toxicity limited hyperbaric oxygen exposure.
Why it matters
Vigabatrin shows robust protection against hyperbaric oxygen-induced seizures in a large-animal model without acute retinal injury. This provides preclinical support for adjunctive therapies during oxygen prebreathing, though pulmonary oxygen toxicity remains an unaddressed limitation.
Limits
The study was conducted in swine rather than humans, and the total sample size was not reported in the abstract. Only acute single-dose effects were evaluated, and vigabatrin did not prevent pulmonary oxygen toxicity.
Cited by
- contradicts Anti-seizure drugs are ineffective at preventing central nervous system oxygen toxicity seizures unless administered at dosages high enough to induce a near-sedated coma.